Home Companies Catalysts Deep Dives
Tecartus brexucabtagene autoleucel APPROVED
Drug Profile
ModalityCell therapy
RouteIV
Therapy AreaOncology
Launch2020-07-24
US LOE2032-07-24
Peak Sales Est$600M
Formulations[{"id":"tecartus-iv","route":"IV","setting":"INPATIENT","frequency":"Single infusion","is_primary":t
Companies
GILD (ORIGINATOR)100%
Mechanism: CD19 CAR-T
Expert: Autologous anti-CD19 CAR T-cell therapy for B-cell malignancies.
Everyday: Patient's own immune cells engineered to attack cancer cells with CD19 marker.
Targets: ["CD19"]
Revenue History
PeriodRevenue ($M)
2023$378M
2024$401M
Q4 2025$90M
2025$344M
Programs (1)
IndicationStageKey StudyRegional Status
r/r MCLAPPROVEDZUMA-2[{"stage":"APPROVED","region":"US","approval_date":"2020-07-24"}]
Notes
CD19 CAR-T for MCL and B-ALL.
Data from Supabase · Updated 2026-03-24